Table 1.
Available drugs and non-vaccine therapeutics, with their target proteins, up to November 2022.
| Therapeutics | Type | Target Protein (SARS-CoV-2) | References |
|---|---|---|---|
| Nirmatrelvir with Ritonavir (Paxlovid) | Antiviral drug | Viral protease (Mpro) | [25,26] |
| Remdesivir (Veklury) | Antiviral drug | RdRp | [27,28] |
| Bebtelovimab | Monoclonal antibody | Spike protein (RBD) | [29,30] |
| Molnupiravir (Lagevrio) | Antiviral drug | RdRp | [31] |
| Bamlavinivmab with etesevimab | Monoclonal antibody | Surface spike glycoprotein | [32] |
| Casirivimab with imdevimab | Monoclonal antibody | Spike protein | [33,34] |
| Sotrovimab | Monoclonal antibody | Spike protein | [35,36] |
| Tixagevimab with cilgavimab | Monoclonal antibody | Spike protein | [37,38] |
Abbreviation: Mpro, main protease; RdRp, RNA-dependent RNA polymerase; RBD, receptor binding domain.